Neuromod Devices Limited (“Neuromod” or “The Company”), the Irish medical technology company specializing in non-invasive neuromodulation technologies, announced that Rosemarie Tully has been appointed Chief Operating Officer (“COO”), effective immediately. Ms Tully most recently held the role of Chief Business Officer, responsible for business development, corporate, and commercial strategy.
In addition to her current responsibilities for corporate development and strategy, Ms Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms Tully will continue to report to Dr Ross O’Neill, Chief Executive Officer of Neuromod.
As COO, Ms Tully will play a key role in supporting Neuromod’s accelerated growth phase as it transitions from a “research and development organization to large-scale manufacturing organization, supporting the commercialization of the Company’s tinnitus treatment device, Lenire,” according to the company’s announcement. As COO, Ms Tully’s key short-term focus will be scaling up manufacturing capacity of the Lenire device to meet anticipated European demand; and implementing regulatory strategy required to support market entry into the United States.
Commenting on the announcement, Dr Ross O’Neill said: “I am delighted to announce Rosemarie’s appointment as Chief Operating Officer. Rosemarie’s broad skill set and extensive international experience in senior leadership roles in the pharma sector have been crucial to the development of Neuromod, since she joined the company in 2018. Rosemarie has also delivered key commercial initiatives like the successful launch of our Lenire brand in Ireland and Germany. As COO she will continue to support myself and our newly appointed Chief Commercial Officer, Florian Elsaesser, as the rollout of our commercial strategy accelerates in key markets.”
Ms Tully is a registered pharmacist, with more than 20 years of industry experience including senior roles in corporate development and strategy at Sigmoid Pharma (now Sublimity Therapeutics), Elan Corporation (now Perrigo), as well as strategy consulting experience at McKinsey & Company. Ms Tully earned her BSc (Pharm) at Trinity College, Dublin, Ireland and an MBA from INSEAD, France.